Co-proxamol and suicide

Licence needs to be changed

Editor—We agree with Hawton et al that co-proxamol presents a major overdose hazard, their results illustrating the difficulties for licensing authorities in limiting availability of prescription medicines that are only hazardous in overdose.1

Co-proxamol is more likely to result in death; it causes prolongation of the QRS interval in an electrocardiogram in experimental animals and in humans.2 This property is usually associated with sodium channel blockade and is a precursor to ventricular arrhythmia. We have shown a significant relation between estimated dextropropoxyphene dose (based on paracetamol concentration) and QRS prolongation in a case of co-proxamol poisoning,3 an effect not seen with other opioid combination products.

Dextropropoxyphene is rapidly absorbed from the gastrointestinal tract, increasing early cardiac risk, with death happening within one hour after ingestion.4 Most patients probably die of co-proxamol poisoning as a result of its combined cardiac (non-opioid) and central nervous system (opioid) effects before hospital admission. Understanding these factors may also improve acute care.

Prescribing patterns for co-proxamol may show geographical variation, which could alter the risk estimates calculated by Hawton et al. In Edinburgh co-proxamol poisoning accounted for 4.8% of 5583 patients admitted with self harm in the two years from July 2000 to June 2002 (overall 20% of patients took an opioid). These figures seem similar to those of Hawton et al.

D N Bateman reader in clinical pharmacology nick.bateman@luht.scot.nhs.uk

R Afshari postgraduate fellow

Scottish Poisons Information Bureau, Royal Infirmary of Edinburgh, Edinburgh EH16 4SA

Competing interests: None declared.

Co-proxamol should be restricted, not banned

Editor—Smith suggests that co-proxamol should be banned.1 I am surprised by this reaction to Hawton et al’s paper on co-proxamol and suicide.2 Hawton et al clearly advocate restricting the availability of co-proxamol.

Dextropropoxyphene is closely related to methadone, and like methadone it has noradrenergic analgesic properties in addition to its opioid effect. Patients who attend pain clinics have often tried several compounds, and occasionally they report that co-proxamol is the most effective. This may reflect a neuropathic component to their pain that is quite different to the post-operative pain for which co-proxamol is no better than paracetamol alone.

The evidence suggests that co-proxamol should be restricted perhaps to specialist use but not banned outright. After all a knee-jerk ban of thalidomide would have deprived patients of a drug still used in the treatment of lepromy.

Ivan L Marples consultant in pain medicine and anaesthesia Western General Hospital, Edinburgh EH4 2XU ivan@doctors.org.uk

Competing interests: None declared.

Availability of co-proxamol has been successfully reduced in Doncaster

Editor—In 1998 an audit of suicides in Doncaster identified the alarming rate of co-proxamol overdose as a method of suicide: of the 44 suicides with prescribed drugs between 1995 and 1998, 18 were with co-proxamol (41%).1 That this is much higher than the national figure of 18% quoted by Hawton et al may be because the rates of prescribing of co-proxamol in Doncaster (around 11 million tablets a year) were 65% higher than the national average.

Hawton et al recommend restricting co-proxamol on the evidence that restricting availability of a specific means of suicide can reduce deaths. Doncaster Health Authority reached the same conclusion in 1998 and undertook to reduce the amount of co-proxamol in circulation by asking general practitioners to be more cautious in prescribing the drug. Doncaster Royal Infirmary also removed co-proxamol from its formulary.

The table shows how, four years on, the policy of reducing prescribing has been successfully implemented: around 60% fewer tablets are currently prescribed than in the period up to 1998 and the prescribing rate is now lower than the national average.

The numbers of suicides among Doncaster residents, also shown in the table, are too small for us to show any relation between the amount of co-proxamol prescribed and the number of suicides with the drug or the total number of suicides. However, we cannot help but be encouraged by the numbers: only five since the beginning of 2000.

The remarkably low number of suicides in 2002 is not a final figure, but many more are unlikely to emerge, and this clearly cannot be attributed to reductions in co-proxamol prescribing. We can, however, be sure that the quantity of tablets in circulation has been massively reduced and that the evidence, as quoted by Hawton et al, implies that this is likely to reduce deaths.

Paul T Fryers public health specialist paul.fryers@doncastereastpct.nhs.uk

Michael Geraghty research and information officer Doncaster East Primary Care Trust, Doncaster DN4 3DJ

Christine Hall director of public health Doncaster West Primary Care Trust, St Catherine’s Hospital, Doncaster DN4 8QN

Competing interests: None declared.

Effectiveness of reducing prescriptions of co-proxamol in Doncaster

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>No of co-proxamol tablets per prescribing unit*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Doncaster</td>
<td>27.8</td>
<td>28.0</td>
<td>26.7</td>
<td>17.6</td>
<td>13.1</td>
<td>11.7</td>
<td>10.7</td>
</tr>
<tr>
<td>England and Wales</td>
<td>16.9</td>
<td>16.7</td>
<td>16.4</td>
<td>15.9</td>
<td>15.1</td>
<td>14.5</td>
<td>13.8</td>
</tr>
<tr>
<td>No of suicides†</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>With co-proxamol</td>
<td>5</td>
<td>3</td>
<td>7</td>
<td>5</td>
<td>2</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>All other methods</td>
<td>25</td>
<td>29</td>
<td>36</td>
<td>22</td>
<td>31</td>
<td>26</td>
<td>14</td>
</tr>
</tbody>
</table>

*Based on data from the Prescription Pricing Authority for preceding eight months for 1996 and on first six months only for 2002.
†Office for National Statistics public health mortality file; data for 2002 not final.
Letters

Antidepressant prescribing and suicide

Analysis is misleading

Editor—Hall et al’s data on suicide rates and antidepressant prescribing contradict their own conclusions.1 The conventional and intuitive way of analysing trends in rates of antidepressant use by age group would be to look at ratios of rates of use in 1998-2001 and 1990-1.

Data on bmj.com show that rates increased 7.5 times for men aged 25-34 and 2.1 times for men aged 75-84. Spearman correlations using these ratios for all age groups and the difference in suicide rates as defined by Hall et al showed a strong positive correlation. Increases in suicide rates were associated with higher rates of increase in the use of antidepressants. For men, Spearman’s correlation coefficient was $r = 0.86$, $P = 0.007$; for women, $r = 0.76$, $P = 0.03$.

Hall et al seem to have analysed absolute differences in rates of prescribing. The use of daily dependent dose is also problematic and not clearly explained. Daily dependent doses represent units of therapeutic doses as defined by the World Health Organization. The increase in the use of antidepressants in older age groups is probably accounted for partly by a change from prescribing lower doses of tricyclic antidepressants to prescribing selective serotonin reuptake inhibitors at standard doses.

Evidence that lower doses of tricyclics are less efficacious than standard doses is not strong.1 In addition, daily dependent doses relate to the general adult population. They will therefore underestimate the true impact of tricyclic antidepressants in elderly people in whom therapeutic and tolerable doses are accepted to be lower.

That the massive increase in antidepressant prescribing has had any objective and positive impact on the health of populations remains difficult to prove. Other commentators have implied that there is no impact on suicide trends and pointed out that rates of self harm are rising, not falling.3 Long term incapacity due to depression in the United Kingdom continued to rise throughout the 1990s.4

Joanna Moncrieff
Senior lecturer
Department of Psychiatry and Behavioural Sciences, University College London, London
WIN 8AA joanna.moncrieff@nclnhs.uk

Competing interests: None declared.


Antidepressants do not reduce suicide rates

Editor—Hall et al show that the biggest increase in the use of antidepressants in 1990-2000 has been in the 15-44 age group.1 Simultaneously the rate of suicide for this age span has increased in Australia. For men aged 25-34 the use of antidepressants has increased more than six times during the period and the suicide rate has increased by almost 17%.

By using this correlation in time in the same way that Hall et al use the total correlation for all ages it could be argued that antidepressants increase the risk of suicide for people younger than 45 and particularly for men aged 25-34. Neither this conclusion nor that of Hall et al is scientifically valid. To make valid conclusions we need controlled studies.

Hall et al say that there is little direct evidence that antidepressants reduce the suicide rate because even large clinical trials have limited power to detect a reduction. They do not mention that three large meta-analyses on antidepressants and suicide have been published since 2000.2-4 Together these include over 60 000 depressed patients in randomised clinical trials comparing antidepressants with placebo. Most trials were short term, but

Competing interests: None declared.


Age specific rates of suicide per 100 000 in white men in the United States1

<table>
<thead>
<tr>
<th>Age group (years)</th>
<th>1940</th>
<th>1975</th>
</tr>
</thead>
<tbody>
<tr>
<td>20-39</td>
<td>23.5</td>
<td>19.2</td>
</tr>
<tr>
<td>40-44</td>
<td>23.5</td>
<td>19.2</td>
</tr>
<tr>
<td>45-54</td>
<td>27.6</td>
<td>24.8</td>
</tr>
<tr>
<td>55-64</td>
<td>31.7</td>
<td>32.1</td>
</tr>
<tr>
<td>65-74</td>
<td>28.7</td>
<td>29.2</td>
</tr>
<tr>
<td>75-84</td>
<td>23.8</td>
<td>25.1</td>
</tr>
</tbody>
</table>


Competing interests: None declared.


Antidepressants do not reduce suicide rates

Editor—Hall et al show that the biggest increase in the use of antidepressants in 1990-2000 has been in the 15-44 age group. Simultaneously the rate of suicide for this age span has increased in Australia. For men aged 25-34 the use of antidepressants has increased more than six times during the period and the suicide rate has increased by almost 17%.

By using this correlation in time in the same way that Hall et al use the total correlation for all ages it could be argued that antidepressants increase the risk of suicide for people younger than 45 and particularly for men aged 25-34. Neither this conclusion nor that of Hall et al is scientifically valid. To make valid conclusions we need controlled studies.

Hall et al say that there is little direct evidence that antidepressants reduce the suicide rate because even large clinical trials have limited power to detect a reduction. They do not mention that three large meta-analyses on antidepressants and suicide have been published since 2000. Together these include over 60 000 depressed patients in randomised clinical trials comparing antidepressants with placebo. Most trials were short term, but
several long term trials were also included, with a total of 1949 patients. The results of all meta-analyses, both for short term and long term treatment, were that suicide was slightly more common among patients taking antidepressants compared with patients taking placebo.

Hall et al do not show that antidepressants reduce the rate of suicide. At the same time, randomized clinical trials show that the rate of suicide is higher with antidepressants than it is with placebo. The only reasonable conclusion is that antidepressants do not reduce the rate of suicide. There may be a slight increase in suicide rates for patients treated with antidepressants, although further studies are needed to make any firm conclusions.

Peter H Ankarberg clinical psychologist
Sanctumcentrum Unia Vuxna, Repslagargatan 5A, S-611 30 Nyköping, Sweden
peter.ankarberg@spray.se

Competing interests: None declared.

Peter H Ankarberg
clinical psychologist
Sanctumcentrum Unia Vuxna, Repslagargatan 5A, S-611 30 Nyköping, Sweden
peter.ankarberg@spray.se

Competing interests: None declared.

Editor

Letters

European Commission’s proposal for a council recommendation on cancer screening

Editor—The European Commission recently published the Proposal for a Council Recommendation on Cancer Screening, based on consensus reached by experts.1 For breast, cervical, and colorectal cancer sufficient evidence has been accumulated on cost effectiveness and negative effects to recommend screening at a population level. Mammography should be offered every two years to women aged 50-69. Periodic Pap smear testing should start before the age of 50 not earlier than the age of 25. Faecal occult blood testing should be recommended to men and women aged 50-74.2 New technologies can be introduced only after their effectiveness and cost effectiveness have been established in randomised controlled trials on public health relevant outcomes. The following methods or policies require evaluation: digital mammography, liquid based cervical cytology, human papillomavirus detection, automated screening devices, immunological faecal occult blood tests, primary colonoscopy, as well as extension of mammographic screening in women aged 40-49. The European Commission recommends that screening be offered in organised programmes, with quality assurance at all levels and good information about benefits and risks. A reduction in mortality and incidence of advanced disease can be achieved only if coverage is high and standards of rigorous quality assurance are respected. Management and evaluation of programmes require accurate monitoring of data. Data transmission


European Commission’s proposal for a council recommendation on cancer screening

Editor—The European Commission recently published the Proposal for a Council Recommendation on Cancer Screening, based on consensus reached by experts.1 For breast, cervical, and colorectal cancer sufficient evidence has been accumulated on cost effectiveness and negative effects to recommend screening at a population level. Mammography should be offered every two years to women aged 50-69. Periodic Pap smear testing should start before the age of 50 not earlier than the age of 25. Faecal occult blood testing should be recommended to men and women aged 50-74.2 New technologies can be introduced only after their effectiveness and cost effectiveness have been established in randomised controlled trials on public health relevant outcomes. The following methods or policies require evaluation: digital mammography, liquid based cervical cytology, human papillomavirus detection, automated screening devices, immunological faecal occult blood tests, primary colonoscopy, as well as extension of mammographic screening in women aged 40-49. The European Commission recommends that screening be offered in organised programmes, with quality assurance at all levels and good information about benefits and risks. A reduction in mortality and incidence of advanced disease can be achieved only if coverage is high and standards of rigorous quality assurance are respected. Management and evaluation of programmes require accurate monitoring of data. Data transmission


European Commission’s proposal for a council recommendation on cancer screening

Editor—The European Commission recently published the Proposal for a Council Recommendation on Cancer Screening, based on consensus reached by experts.1 For breast, cervical, and colorectal cancer sufficient evidence has been accumulated on cost effectiveness and negative effects to recommend screening at a population level. Mammography should be offered every two years to women aged 50-69. Periodic Pap smear testing should start before the age of 50 not earlier than the age of 25. Faecal occult blood testing should be recommended to men and women aged 50-74.2 New technologies can be introduced only after their effectiveness and cost effectiveness have been established in randomised controlled trials on public health relevant outcomes. The following methods or policies require evaluation: digital mammography, liquid based cervical cytology, human papillomavirus detection, automated screening devices, immunological faecal occult blood tests, primary colonoscopy, as well as extension of mammographic screening in women aged 40-49. The European Commission recommends that screening be offered in organised programmes, with quality assurance at all levels and good information about benefits and risks. A reduction in mortality and incidence of advanced disease can be achieved only if coverage is high and standards of rigorous quality assurance are respected. Management and evaluation of programmes require accurate monitoring of data. Data transmission


European Commission’s proposal for a council recommendation on cancer screening

Editor—The European Commission recently published the Proposal for a Council Recommendation on Cancer Screening, based on consensus reached by experts.1 For breast, cervical, and colorectal cancer sufficient evidence has been accumulated on cost effectiveness and negative effects to recommend screening at a population level. Mammography should be offered every two years to women aged 50-69. Periodic Pap smear testing should start before the age of 50 not earlier than the age of 25. Faecal occult blood testing should be recommended to men and women aged 50-74.2 New technologies can be introduced only after their effectiveness and cost effectiveness have been established in randomised controlled trials on public health relevant outcomes. The following methods or policies require evaluation: digital mammography, liquid based cervical cytology, human papillomavirus detection, automated screening devices, immunological faecal occult blood tests, primary colonoscopy, as well as extension of mammographic screening in women aged 40-49. The European Commission recommends that screening be offered in organised programmes, with quality assurance at all levels and good information about benefits and risks. A reduction in mortality and incidence of advanced disease can be achieved only if coverage is high and standards of rigorous quality assurance are respected. Management and evaluation of programmes require accurate monitoring of data. Data transmission
and linkage systems must be set up with respect of privacy legislation and ethical rules. The European Commission has given the network for cancer screening the mandate to work out technical guidelines defining standards and benchmarks for best practice. The current proposal still needs endorsement by the ministers of health. We hope this will happen without delay.

Marc Arbyn coordinator, evaluation of new screening methods, European Network for Cervical Cancer Screening marc.arbyn@iph.fgov.be

Herman Van Oyen head, unit of epidemiology Scientific Institute of Public Health,Julian Wijnstraat 14, B-1050 Brussels, Belgium

Elsebeth Lynge head Institute of Public Health, University of Copenhagen, Copenhagen, Denmark

Michael Mickische head Department of Applied and Experimental Oncology, Institute of Cancer Research, University of Vienna, Vienna, Austria

Jean Faivre head Registre Bourguignon des Cancers Digestifs, Faculté de Médecine, Dijon, France

Jose Jordan president, European Federation for Cologastroenterology Birmingham Women’s Hospital, Birmingham

Competing interests: None declared.

Opportunistic screening for Chlamydia

Microbiological input is essential in Chlamydia screening programmes

Editor—The strand displacement amplification test used by Moens et al for Chlamydia trachomatis screening produced equivocal results in 11.2% of samples.1 Such a high rate is unacceptable. A result could be termed equivocal if it is borderline or if a sample gives discrepant results on repeat testing. In addition, this assay has an internal control, a negative result being invalid if the internal control is inhibited. Differentiation between these potential causes is important—borderline and non-repeatable positive results could be due to small amounts of organisms or technical problems such as cross contamination; inhibitors may be prevented by cold chain transportation of urine or by using the urine processing pouch supplied by the manufacturer.

We have extensive experience with the strand displacement amplification test and have not experienced such a problem with equivocal results. Of 24 130 samples tested, 21 605 (89.5%) were negative while 2224 (9.2%) were repeatable positive results. Only 72 samples gave non-repeatable positive results (prevalence 0.3%), reproducibility rate 96%).2 229 samples (0.9%) had evidence of inhibitors. Thus, only 1.2% of the samples gave no definitive positive or negative result. Although treating all equivocal results as positive is a pragmatic approach, action based on poor quality results will lead to misleading reports, inappropriate labelling of patients as having sexually transmitted infections, unnecessary partner notification, overtreatment with antibiotics, inaccurate statistics, and incorrect epidemiological analysis. Active microbiological input is essential during the planning of such programmes to optimise sample collection and transportation as well as the interpretation of results.

C Y William Tong consultant virologist, department of infection william.tong@gstt.sthames.nhs.uk

Helen Dunn diagnostic service manager, department of infection

David A Lewis consultant physician, department of genitourinary medicine

Carr’s and St Thomas’s Hospital Trust, London SE1 7EH

Competing interests: None declared.


Authors’ reply

Editor—We acknowledge the concerns of Tong et al and fully endorse their view that active microbiological input is essential both in planning and introducing a Chlamydia screening service using the strand displacement amplification test.

We emphasise that our study was carried out with input from the medical microbiology department that did the testing, which also, as stated in the paper, was informed of our concerns about the high number of equivocal results but could not provide an explanation. Apparently the problem was not confined to samples from our clinic.

We explain in the paper why we decided not to offer a repeat test and instead treat the equivocal result as positive—namely, because we were not confident, given our experience of the high risk client group being tested, that these young clients would return for a repeat test.

Since completing the study, which included as part of the service an information campaign and outreach work in a local school informing pupils about Chlamydia and our service, we are much more confident about successfully being able to recall clients who have an equivocal result for a repeat test. Moreover, the rate of equivocal results has fallen to around 1% of samples, perhaps indicating improved procedures with the strand displacement amplification test.

Veronique Moens family planning doctor

Geoffrey Baruch director

GBaruch@compuserve.com

Brandon Centre for Counselling and Psychotherapy for Young People, London NW5 3LG

Competing interests: None declared.

Guidelines for anecdotes might include more information

Editor—We agree with Aronson on the need for a uniform presentation of anecdotes and case reports by using common standardised guidelines.1 His proposed guidelines are complete and systematic, but some items could be added to improve this format. In the drug treatment section, the contents should include prescription drugs, over the counter medicines, and preparations of complementary and alternative medicines, including herbal treatments and homoeopathic and ethnic preparations. The use of these treatments has increased over the past years, mainly in patients with chronic diseases who are taking multiple drugs, in whom adverse reactions are more likely to develop.

In the history section, it is important to include history of use of psychostimulant substances (such as methylxanthines) and natural or synthetic drugs of abuse (such as cannabis, amphetamines, hallucinogens, or opiates), in addition to drinking and smoking habits.

Other aspects to consider are the compulsory communication of the adverse reaction to the national pharmacovigilance centre or the local World Health Organization drug monitoring programme before submitting a paper for publication.

Sergio Abanades clinical pharmacology resident

sahabanes@min.es

Mag Farre consultant clinical pharmacology

mfarre@min.es

Pharmacology Unit, Institut Municipal Investigació Medica, Hospital del Mar, Universitat Autònoma de Barcelona, Dr Aliguer 80, Barcelona 08005, Spain

Competing interests: None declared.

1 Aronson JK. Anecdotes as evidence. BMJ 2003;326:1346. (21 June.)

Two groups were different in cardiovascular risk study

Editor—Dundur et al compared two different groups and concluded that the incidence of myocardial infarction was significantly higher in the group receiving antihypertensive treatment.1 Table 1 shows two heterogeneous groups—the group with hypertension (having treatment) had higher blood glucose concentrations, body mass index, and proinsulin values (implying insulin resistance) than the other group, which had normal blood pressure, lower body mass index, and lower glucose concentrations (implying insulin sensitivity). Up to 40% of patients with hypertension are insulin resistant, and insulin resistance is associated with increased cardiovascular risk.2 Thus the group with hypertension was at a much higher baseline risk of cardiovascular disease than the group with normal blood pressure.

The two groups remain significantly different over the next 10 years. The normal blood pressure group showed less increase in body mass index and glucose concentrations. Dundur et al say that an increase in
fasting blood glucose predicted myocardial infarction in the group receiving antihypertensive treatment but not in the group without such treatment. However, 5-7% of patients with insulin resistance progress to the next stage of glucose dysregulation yearly. If we presume that 30% of patients with hypertension in this study had insulin resistance then around 1% per year (about 10% over 10 years) of this group would progress to the next stage of insulin dysregulation, irrespective of the treatment.

The conclusion(s) of the study would have been appropriate had Dunder et al compared hypertensive patients receiving treatment with those not receiving such treatment when their baseline risk(s) for development of cardiovascular disease would have been similar.

Although hypertension and diabetes are additive, hypertension seems to be a more potent predictor of vascular risk than glycaemic control, and aggressive treatment of hypertension dramatically reduces this risk.1

Malvinder S Parmar medical director (internal medicine)
Timmins and District Hospital, Timmins, ON, Canada P N 8 R1
arbeeat@nfrl.sympatico.ca

Competing interests: None declared.


What is also interesting is that with a few exceptions, doctors have not subjected these interventions to rigorous study.1 If they prove to be as effective as many believe them to be, the knowledge will transform the management of all patients with lower urinary tract symptoms and could potentially impact on 60% of the men and women over the age of 50.

Tim Lane clinical lecturer in urological oncology Department of Medical Oncology St Bartholomew's Hospital, London E1A 7BE
MrTMLane@aol.com

Christian Brown research fellow Clinical Effectiveness Unit, Royal College of Surgeons, London WC2A 3PE

Mark Emberton senior lecturer Institute of Urology, University College London, London W1P 7PS

Competing interests: None declared.


Randomisation foundation trusts

Editor—Yet another NHS policy initiative is being introduced in a form that does not allow the taxpayer and voter to assess whether the change is helpful or not. Because potential foundation trusts are different from the “average” trust then any effect they have on the delivery of health care will be confounded either by selection bias or through regression to the mean.

The 32 trusts expressing an interest in foundation status should be randomised to give the status or remain as they are. We will then be able to ascertain whether they work or not. What is likely to happen is that they will be evaluated (if they are evaluated at all) by using non-randomised methods. For critics of foundation trusts a before and after design is likely to be helpful in “proving” such trusts are harmful.

As they are selected on the basis of “high” performance there ought to be a satisfying effect they have on the delivery of health care supported by the permanent secretary in the Department of Health. With an adequate budget the improvements in cancer services might be replicated in other areas of the NHS.

Ian H Runkler consultant in clinical oncology Eastern General Hospital, Edinburgh EH2 2XU
i.runcker@eal.ac.uk

Competing interests: None declared.

1 Smith R. Changing the ‘leadership’ of the NHS. BMJ 2003;326:6. (21 June.)

“Hitting the Headlines” is useful resource

Editor—Switzer reviewed the media and evidence.1 One of my favourite sections of the UK National Electronic Library for Health site (www.nell.nhs.uk) is Hitting the Headlines, produced by the NHS Centre for Reviews and Dissemination.

It takes articles from the British national press that report on issues relating to the effectiveness of an intervention. It then assesses the reliability of the claims by critically appraising the underlying research. It cannot stop the flow of “distorted” articles produced by the national press, but it can provide a useful resource for clinicians in protecting themselves from hordes of newspaper waving patients.

Jon R BrasseY director, TRIP database National Public Health Service Wales, Pontypool NP4 0YP
jon@tripdatabase.com

Competing interests: JRB works on a variety of projects for the National Electronic Library for Health, but not Hitting the Headlines.

1 Switzer G. How the media left the evidence out in the cold. BMJ 2003;326:403-4. (21 June.)